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Astudywasperformedtoidentifyvariablesthataﬀectedcause-speciﬁcsurvival(CSS)andlocalrelapse-freerate(LRFR)inpatients
withdiﬀerentiated thyroid cancer (DTC) and extrathyroid extension (ETE) and to examine the role of external beam radiotherapy
(XRT). Prognostic factors were similar to those found in studies of all patients with DTC. In patients with postoperative gross
residual disease treated with radiotherapy, 10-year CSS and LRFR were 48% and 90%. For patients with no residual or microscopic
disease, 10-year CSS and LRFR were 92% and 93%. In patients older than 60 years with T3 ETE but no gross residual disease
postoperatively there was an improved LRFR at 5 years of 96%, compared to 87.5% without XRT (P = .02). Patients with gross
ETE beneﬁt from XRT and there may be a potential beneﬁt in reducing locoregional failure in patients over 60 years with minimal
extrathyroidal extension (T3).
1.Introduction
Theroleofradiotherapyinthemanagementofdiﬀerentiated
thyroid cancer remains controversial with the majority of
patients treated with thyroidectomy and radioactive iodine
alone [1]. However, there is a subset of patients who are at
high risk for local recurrence who may beneﬁt from adjuvant
external radiation therapy. The diﬃculty in determining the
optimal management of patients is the lack of random-
ized control trials and the reliance on single institution
prospective databases and retrospective reviews, complicated
by changes in clinical practice, pathology assessment, and
surgical techniques over time. Despite this, the British
Thyroid Association recommends XRT in patients over 60
years of age with extensive extranodal spread after optimal
surgery, even in the absence of evident residual disease
[2], and the American Thyroid Association guidelines have
recommended that “The use of external beam irradiation
should be considered in patients over age of 45 with grossly
visible extrathyroidal extension (T4a and T4b) at the time
of surgery and a high likelihood of microscopic residual
disease” [3].
Several factors have been identiﬁed to be prognostic
in determining survival. These factors include age, tumor
size, grade, presence of macroscopic disease after surgical
resection, and presence of distant metastases [4, 5]. Addi-
tionally extrathyroidal extension (ETE) has been identiﬁed
as carrying a higher risk for local recurrence [4, 6, 7].
The deﬁnition of the AJCC and UICC T Category for
thyroid cancer changed in 2002 and reﬂects the impor-
tance of varying degrees of ETE [8, 9]. There are three
diﬀerent levels of extent. T3 represents minimal ETE to
sternothyroidorperithyroidtissueoranytumorgreaterthan
4cm. T4a includes invasion into subcutaneous soft tissue,
larynx, trachea, esophagus, and recurrent laryngeal nerve.
T4b includes invasion into prevertebral fascia, mediastinal2 Journal of Thyroid Research
vessels, or encasement of the carotid artery. In a retrospective
review of 1067 patients with ETE treated by surgery alone,
Ito et al. reported that minimal ETE (T3) did not have a
deleterious eﬀect on relapse-free survival (RFS) compared to
no extrathyroidal extension, but that massive ETE (T4) did
[10].
An analysis of a retrospective study from Princess Mar-
garet Hospital (PMH) has previously shown that patients
overtheageof60withETEandnogrossresidualdiseaseafter
surgery had signiﬁcantly improved 10-year cause-speciﬁc
survival (CSS) (81.0% versus 64.6%, P = .04) and 10-
year local relapse-free rates (LRFRs) (86.4% versus 65.7%,
P = .04) following adjuvant external radiation therapy
[11]. Patients under 60 had improved local control, but
not survival. The indications for radiotherapy at PMH have
changed and have been reﬁned over the years. Currently,
the indications for XRT are patients over the age of 45
years with T4a or T4b tumors, or gross residual disease
following thyroidectomy. Previously XRT was considered in
all patients with ETE, but radiotherapy is now not advised
for patients with T3 tumors (minimal ETE). This study is a
retrospective review performed to further assess the role of
XRT in patients with ETE and identify prognostic factors for
local relapse-free rates and cause-speciﬁc survival in patients
with diﬀerentiated thyroid cancer and ETE that might help
more clearly to deﬁne who are at high risk and may beneﬁt
fromXRTandtotestthehypothesesthatyoungpatientswith
T4b disease beneﬁted from XRT while older patients with T3
disease did not.
2.MaterialsandMethods
Following local ethics review board approval, a retrospective
chart review of 323 patients with diﬀerentiated thyroid
carcinoma (papillary or follicular) and known ETE, referred
for adjuvant management and registered between January
1958 and December 1999, was conducted. The identiﬁcation
of 369 potentially eligible patients was previously described
by Brierley et al. [11]. The pathology slides of all patients
were reviewed at PMH on referral. As in our previous
study, because of changes in the distribution of patients with
follicular as opposed to papillary thyroid cancer, presumably
due to changes in pathologists interpretation, patients with
papillaryorfolliculartumorswereanalyzedtogether[11].Of
the 369 patients, nine were not considered due to diﬃculty
in obtaining the source documentation for this chart review,
and a total of 37 patients were excluded because they were
referred for recurrent disease, for followup with primary
treatment elsewhere, and for second opinion, or they had
distant metastatic disease at presentation.
The sample size was not based on prestudy consid-
erations of statistical power but on the available number
of patients within the relevant time period. Cause-speciﬁc
survival (CSS) and local relapse-free rates (LRFRs) were
calculated by the cumulative incidence method. LRFR
was deﬁned as freedom from relapse in the neck, either
thyroid bed or cervical lymph nodes, based on clinical
examination or diagnostic imaging. Using the cumulative
incidence method, competing risks were not censored,
but acknowledged in the calculation. For CSS, the com-
peting event was death from among other causes. For
LRFR, competing events included deaths or metastatic
failures
Univariate log-ranktesting andmultivariate Coxpropor-
tional hazards regression modeling analysis were performed
on prognostic variables; this included the eﬀect of treatment.
Variables examined were histology, gender, age, tumor size,
Tc a t e g o ry ,d i ﬀerentiation, nodal involvement, postoperative
status, multifocality, margin status, and lymphovascular
involvement. In accordance with previous analyses from
our institution, age was analyzed as a continuous variable
a n do nac a t e g o r i c a lb a s i s( <45, 45–60, >60) [5, 11, 12].
Tumor size was recorded and analyzed as a categorical
variable, not a discrete variable; as in previous analyses, the
categorical variables were <1cm, ≥1cm and <4cm, and
≥4cm as per earlier editions of TNM. Extent of ETE was
categorized according to TNM 6th edition [8, 9]. Patients
with metastatic disease on ﬁrst posttherapy radioactive
iodine scan were considered to have metastases at time of
presentation. Followup data was obtained through a review
of patient charts and electronic records. For patients that
were not routinely followed at PMH, questionnaires were
sent to attending physicians, followup phone calls were
made to attending physicians, and cancer registry data was
reviewed.
As a result of multiple signiﬁcance testing (from the
prognostic factor analysis and several subgroup analyses,
on two endpoints) the Type I error is inﬂated so it is
plausible that some of the eﬀects presented as statistically
signiﬁcant are spurious. However, as it has been argued
that the adjustment of P-values with the Bonferroni method
cr eat esmor epr oblemsthanitsol v es[13],theP-valuesinthis
report are unadjusted for multiple comparisons. Moreover,
giventhelimitedsamplesize,oursubgroupanalyseshavelow
power (i.e., an inﬂated Type II error) to detect statistically
signiﬁcant diﬀerences. Competing risk failure probabilities
and plots were produced with the cmprsk package using
version 2.6.0 in R. All other analyses were performed using
SAS version 9.1.
3. Results
3.1. Patient Characteristics. The distribution of patient char-
acteristics, candidate prognostic factors and treatments, are
summarized in Table 1. The median followup among living
cases (n = 235) was 10.8 years with a range from 0.6 to 39.5
years. The overall 5- and 10-year local relapsefree rates are
92.5% (SE 0.02%) and 91.7% (SE 0.02%), respectively. Of
323 patients, 56 have failed locally or regionally. The overall
5- and 10-year cause-speciﬁc survival rates are 89.8% (SE
0.03%) and 85.4% (SE 0.04%), respectively (Figure 1). Of
323 patients, 88 died; 46 died of disease and 37 died of other
causes. In 5 cases, the cause of death was unclear. Of patients
who had data regarding site of disease at time of death, 71%
had distant metastasis, while 29% had local regional disease
alone.Journal of Thyroid Research 3
Table 1: Distribution of candidate prognostic factors and treat-
ments.
All N = 323
N %
Histology
Follicular 60 18.58
Papillary 261 80.80
Gender
Female 239 73.99
Male 84 26.01
Age
<45 134 41.49
45–60 95 29.41
>60 93 28.79
Size
<1cm 20 6.19
1–4 cm 187 57.89
>4cm 72 22.29
Diﬀerentiation
Moderate 37 11.46
Poor 52 16.10
Well 98 30.34
Nodal involvement
No 148 45.82
Yes 149 46.13
Postoperative status
Gross 28 8.67
No residual/microscopic 259 80.19
Multifocal
No 187 57.89
Yes 119 36.84
Margin status
Negative 195 60.37
Positive 92 28.48
LVI (Lymph vascular Invasion)
No 87 26.93
Yes 130 40.25
Tc a t e g o r y
3 169 52.32
4a 91 28.17
4b 58 17.96
Surgery
Biopsy 22 6.81
Lobectomy 64 19.81
Near total 80 24.77
Radical 7 2.17
Total 146 45.20
RAI (Radioactive Iodine)
No 65 20.12
Yes 258 79.88
XRT
No 115 35.60
Yes 208 64.40
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Figure 1: Cause-speciﬁc survival and local recurrence-free rate
for patients with diﬀerentiated thyroid cancer and extrathyroidal
extension. The overall 5- and 10-year cause-speciﬁc survivals are
89.8% (SE 0.03%) and 85.4% (SE 0.04%), respectively. The overall
5- and 10-year local relapse-free rates are 92.5% (SE 0.02%) and
91.7% (SE 0.02%), respectively.
3.2. Prognostic Factor and Eﬀects of Treatment Analyses: Base-
line Variables. The candidate prognostic factors and eﬀects
of treatment on cause-speciﬁc survival and local relapse-free
rates were subjected to univariate and multivariate analyses.
Local invasion of subsites (i.e., larynx, trachea, esophagus,
prevertebral fascia, mediastinal vessels, etc.) for T4a and T4b
was collected but not included in the analysis as the number
of events for each subsite was small.
Factors found to be signiﬁcant for a worse cause-speciﬁc
survival on univariate analysis are listed in Table 2.U n e x -
pectedly patients with multifocal disease had better cause-
speciﬁc survival. With respect to treatment, no diﬀerence
in cause-speciﬁc survival was observed in patients receiving
radioactive iodine ablation. Patients who underwent near
total thyroidectomy had better outcomes. The factors which
carried a statistically signiﬁcant association with outcome on
univariate analysis for local relapse rates are listed in Table 2.
T category was not a statistically signiﬁcant prognostic factor
for local relapse-free rates. Treatment modalities (radioactive
iodine ablation, XRT, and surgery) did not inﬂuence overall
local relapse-free rates. However, surgery was of borderline
signiﬁcance.
Multivariate analysis was performed on the majority
of candidate prognostic factors found to be signiﬁcant on
univariate testing (Table 3). The factors statistically signiﬁ-
cant for improved cause-speciﬁc survival were postoperative
status (no residual), papillary histology, and younger age—
<45. The presence of multifocal disease remained a signiﬁ-
cant favorable prognostic factor for cause-speciﬁc survival.
Smaller tumor size (<1cm and 1–4cm) and postoperative
status (no residual) were signiﬁcant for improved local4 Journal of Thyroid Research
Table 2: Univariate analysis and Log-rank P value: summary.
Variable CSS LRFR
Histology (N = 321) <0.0001 0.15
Gender (N = 323) 0.51 0.39
Age (N = 322) <0.0001 <0.0001
Diﬀerentiation (N = 187) <0.0001 0.034
Tumor size (N = 279) 0.002 0.0004
Postoperative status (N = 309) <0.0001 <0.0001
Neck metastasis (N = 297) 0.74 0.06
Multifocal (N = 306) 0.009 0.96
Margin status (N = 287) 0.005 0.65
LVI (N = 217) 0.0006 0.09
Tc a t e g o r y( w o r s to fp a t h o l o g y / O R )( N = 322) 0.014 0.24
RAI (N = 323) 0.62 0.13
RT (N = 323) 0.01 0.71
SURGERY (N = 290) 0.01 0.074
relapse-free rates. There was a trend towards signiﬁcance
with age (P = .09). There was no eﬀe c tf r o mT( T 3 ,T 4 a ,o r
T4b) category for CSS or LRFR on the multivariate model.
No association was seen between treatment modalities and
improved cause-speciﬁc survival or local relapse-free rates.
3.3. Subgroup Analyses. In 40 patients with postoperative
gross residual disease treated with radiotherapy, 10-year CSS
and LRFR were 48% and 90%, respectively (Figure 2). Fur-
ther subgroup analyses were performed in patients without
grossresidualdiseaseaftersurgery,thatis,noresidualdisease
or microscopic residual. Patients were subdivided based on
age (less than 45 years, 45–60 years, and greater than 60
years) and extent of extrathyroidal extension (T3, T4a, and
T4b). Patients were also analyzed based on a combination
of age and T category. XRT did not result in any signiﬁcant
diﬀerence in CSS for any subgroup. There was a trend in
favor of improved LRFR in T3 tumors with XRT (94.8%
versus 87.3% at 5 years, P = .08). There was a signiﬁcant
beneﬁt in patients over 45 with T3 disease treated with
XRT at 5 years. The LRFRs were 96.8% versus 90%, P =
.03, (Figure 3), although in this subgroup there was a trend
towards more use of RAI in patients who also had XRT.
There was however no signiﬁcant diﬀerence in LRFR for
patients between 45 and 60, with the beneﬁt being in those
over 60 (96% versus 87.5%, P = .02, Figure 4), and in this
subgroup there was no diﬀerence in the use of RAI although
the number of patients was small. There was no beneﬁt with
XRT in T3 patients less than 45. Also there was no apparent
beneﬁt to XRT for local relapse-free rates in T4 tumors in
those less than 45 years or greater than 60 years, but the
numbers were relatively small.
4. Discussion
This study demonstrates a potential beneﬁt to radiotherapy
in reducing locoregional failure in patients over 60 years
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Figure 2: Cause-speciﬁc survival and local recurrence-free rate for
patientswithgrossresidualdiseasetreatedwithRT;10-yearCSSand
LRFR were 48% and 90%, respectively.
with minimal extrathyroidal extension (T3). The role of
XRT in diﬀerentiated thyroid cancer remains unclear due
to the lack of prospective randomized studies and the
reliance on evidence from retrospective studies. The use of
XRT in the management of thyroid cancer varies among
centers,butseveralretrospectivestudieshaveshownabeneﬁt
with radiotherapy [14–22] and it is now recommended by
several treatment guidelines in certain high-risk groups [2,
3, 23, 24]. Our current indications for adjuvant radiotherapy
include patients over the age of 45 years with gross residual
disease or over 45 years with clinical gross extrathyroidal
invasion (T4), but not for patients with T3 tumors (minimal
ETE).Journal of Thyroid Research 5
Table 3: Multivariate analysis summary—Cox proportional hazards modeling. (∗∗)
CSS (N = 253 with 26 events) LRFR (N = 263 with 41 events)
Variable Hazard ratio (HR) (95%
conﬁdence interval (CI))
P value HR (95% CI) P value
Histology 8.7 (3.6–21.0) <.0001
Age 3.1 (1.2–8.2) .02 1.8 (0.9–3.7) .09
Diﬀerentiation (∗)
Tumor size 1.8 (0.7–4.6) .25 2.1 (1.04–4.1) .04
Postoperative status 7.1 (2.6–19.6) .0001 4.6 (2.2–9.8) <.0001
Neck metastasis 1.4 (0.8–2.7) .26
Multifocal 0.3 (0.1–0.9) .026
Margin status 1.3 (0.5–3.4) .56
LVI (∗)
Tc a t e g o r y( w o r s to fp a t h o l o g y / O R ) 1.2 (0.5–3.3) .68
RAI 0.5 (0.1–1.9) .29 0.9 (0.3–2.4) .76
RT 0.9 (0.3–2.8) .81 1.4 (0.7–2.9) .36
SURGERY 0.6 (0.2–1.7) .36 1.03 (0.5–2.0) .93
(∗) Not considered in the multivariate analysis because of the extent of missing data.
Note. Cox model was stratiﬁed by 3 approximately equal time periods: 1958–1971, 1972–1985, and 1986–1998 [11].
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Figure 3: Local recurrence-freerateforpatientsover 45years ofage
with T3 tumors treated with and without RT, 96.8% versus 90% at
5 years, respectively, P = .03.
Age has been shown to be a signiﬁcant factor for
determiningprognosisindiﬀerentiatedthyroidcancerthatis
theonlytumortypeinwhichtheAJCCandUICCuseagefor
stage determination. Our previous study in [11] and another
in [25] showed a greater worsening of outcome for patients
over 60 years of age. Extrathyroidal extension has also been
identiﬁed as a prognostic factor carrying a higher risk for
local recurrence [5–7]. Following our recent retrospective
analysis of adjuvant radiotherapy although no beneﬁt to
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Figure 4: Local recurrence free rate for patients over 60 years of age
with T3 tumors treated with and without RT, 96% versus 87.5%, at
5 years, respectively, P = .02.
adjuvant radiotherapy was seen in patients less than 60
years with ETE, we speculated that, since the deﬁnition
of ETE encompasses a large range of disease extent from
minimal invasion of perithyroidal fat to invasion of the
prevertebral fascia, there might still be a beneﬁt to adjuvant
radiotherapy in carefully selected high-risk patients under 60
years. Conversely, we also speculated that there might be a
subset of patients over 60 years with minimal ETE that did
not beneﬁt from adjuvant radiotherapy.6 Journal of Thyroid Research
We were unable to demonstrate a beneﬁt with radio-
therapy for cause-speciﬁc survival and local relapse-free
rates in T4 tumors in those less than 45 years, but the
number of events was small. Also no beneﬁt was seen with
radiotherapy in those over 60 years with T4 disease and
also the number of events was small. There was a signiﬁcant
beneﬁt for local relapse-free rates, but not for cause-speciﬁc
survival in patients over 60 years with T3 disease treated
with radiotherapy. This beneﬁt in patients with T3 disease
was unexpected especially in light of the ﬁndings of Ito et al.
that minimal ETE did not carry a poor prognosis for RFS for
patients over the age of 45 [10], although they did not report
whether there was a diﬀerence in RFS in T3 tumors by age
greaterorlessthan60.Itcouldbespeculatedthatforpatients
greater than 60 there is a diﬀerence in outcome for patients
with limited ETE (seen only microscopically), compared
with those tumors with invasion into sternothyroid or
perithyroidtissuesnotedatthetimeofsurgery.Thepotential
beneﬁt of XRT if it really exists is small in T3 disease and
the data should not be overinterpreted given that this is a
retrospective review of patients seen over a long-time period
with changing practices in surgery, radiotherapy, and the
use of iodine. Another caveat is that multiple statistical
comparisons were explored in subgroups, which increased
the chances of ﬁnding a signiﬁcant diﬀerence by chance
alone.
The beneﬁt of radiotherapy in diﬀerentiated thyroid
cancers with gross residual disease has been shown in
several studies [14, 15, 17, 18]. Chow and colleagues [26]
demonstrated that extent of postsurgical residual disease
was associated with cause-speciﬁc survival and that, when
this factor was included in multivariate analysis, it overrode
the other prognostic factors (size of tumor, extrathyroidal
extension, lymph node metastases, and type of surgery).
Analysis from our institution has also found postoperative
presence of macroscopic residual disease to be a signiﬁcant
factor for 10-year local relapse-free rates and cause-speciﬁc
survival [5]. In this study, patients with postoperative gross
residual disease treated with radiotherapy had 10-year cause-
speciﬁc survival and local relapse-free rates of 48% and 90%,
respectively, demonstrating that even if disease is controlled
in the neck there is a high risk of death from distant
metastatic disease.
5. Conclusions
Prognostic factors for patients with ETE are similar to those
of any patient with diﬀerentiated thyroid cancer. Although
radiotherapy is of beneﬁt in patients with gross residual
disease, we were unable to deﬁne a subset of patients less
than 45 years who beneﬁted from adjuvant radiotherapy.
There may be a potential beneﬁt to radiotherapy in reducing
locoregional failure in patients over 60 years with minimal
extrathyroidal extension (T3). There remains uncertainty in
how to select high-risk patients for radiotherapy. The poten-
tial beneﬁt needs to be balanced against the generally excel-
lent outcomes with surgery and radioactive iodine as well as
the expected side eﬀects of radiotherapy, although these may
be reduced with modern radiation techniques [27].
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